Mineralys Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to target diseases driven by abnormally elevated or dysregulated aldosterone. The company's primary product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI). Lorundrostat is designed to reduce aldosterone levels by selectively inhibiting CYP11B2, the enzyme responsible for producing aldosterone, without interfering with other essential hormones such as cortisol. The therapeutic focus spans cardiorenal conditions, including uncontrolled or resistant hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Repurchased all potential future royalty payments due to Tanabe Pharma Corporation related to lorundrostat, securing an exclusive, worldwide, royalty-free, perpetual license and removing diligence obligations.
Expected impact: Eliminates all future royalty obligations, allowing Mineralys to capture full incremental value from future potential sales of lorundrostat.
Priced a $150 million underwritten public offering of common stock and secured an up to $500 million senior secured term loan facility from Pharmakon Advisors.
Expected impact: Provides the capital necessary to fund the $200 million Tanabe royalty buyout and supports the upcoming commercial launch preparations for lorundrostat.
Building out market access, medical affairs, and commercial preparation teams ahead of the potential FDA approval of lorundrostat.
Expected impact: Ensures commercial readiness and rapid market penetration upon potential FDA approval.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secured perpetual, royalty-free global rights to lead candidate lorundrostat and terminated the original restrictive licensing agreement, with Tanabe assigning remaining IP rights to Mineralys.
Terms: $200 million upfront payment, up to $100 million in new commercial milestones, and up to $165 million in existing commercial milestones.
Provides a non-dilutive capital source to fund the royalty buyout and support commercialization activities.
Terms: $500 million senior secured term loan facility available in four tranches, with $100 million funded at closing; 5-year maturity (June 2031) bearing interest at SOFR (minimum 3.25%) plus 5.50%.